Drug intelligence / Profile preview

PulmoPaint

Development stage: Preclinical
Lead developer: Paint Therapeutics
Modality: Nanoparticles → Drug Delivery Systems
Administration: Inhalation (inferred From Intended Use In Lungs)

Overview

PulmoPaint is a proprietary drug platform under development by Paint Therapeutics, designed for targeted delivery and imaging within the lungs. The technology appears to focus on immune potentiating approaches for lung-resident cancers and other pulmonary diseases. While specific molecular details, active ingredients, or mechanisms of action are not publicly disclosed, the name suggests a modality that "paints" or labels lung tissue—potentially for diagnostic imaging or targeted therapy. The product line is in preclinical or early clinical development stages and aims to address unmet needs in pulmonary oncology and possibly other respiratory conditions[8].

Brand names: PulmoPaint
Other names: PulmoPaint

Beyond the preview

Go deeper on PulmoPaint.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PulmoPaint.

Explore the full profile